Computational Fluid Dynamics for the Prediction of Endograft Thrombosis in the Superficial Femoral Artery

Lennart van de Velde, MSc, BM1,2,3, Erik Groot Jebbink, PhD1,2,4, Rob Hagmeijer, PhD4, Michel Versluis, PhD3,5, and Michel M. P. J. Reijnen, PhD1,2,6

Abstract

Purpose: Contemporary diagnostic modalities, including contrast-enhanced computed tomography (CTA) and duplex ultrasound, have been insufficiently able to predict endograft thrombosis. This study introduces an implementation of image-based computational fluid dynamics (CFD), by exemplification with 4 patients treated with an endograft for occlusive disease of the superficial femoral artery (SFA). The potential of personalized CFD for predicting endograft thrombosis is investigated.

Materials and Methods: Four patients treated with endografts for an occluded SFA were retrospectively included. CFD simulations, based on CTA and duplex ultrasound, were compared for patients with and without endograft thrombosis to investigate potential flow-related causes of endograft thrombosis. Time-averaged wall shear stress (TAWSS) was computed, which highlights areas of prolonged residence times of coagulation factors in the graft.

Results: CFD simulations demonstrated normal TAWSS (>0.4 Pa) in the SFA for cases 1 and 2, but low levels of TAWSS (<0.4 Pa) in cases 3 and 4, respectively. Primary patency was achieved in cases 1 and 2 for over 2 year follow-up. Cases 3 and 4 were complicated by recurrent endograft thrombosis.

Conclusion: The presence of a low TAWSS was associated with recurrent endograft thrombosis in subjects with otherwise normal anatomic and ultrasound assessment and a good distal run-off.

Keywords
computational flow dynamics, peripheral artery disease, stent thrombosis, hemodynamics, wall shear stress

Introduction

For complex above-the-knee femoropopliteal artery occlusive disease, heparin-bonded covered endografts have shown superior patency rates compared to bare metal stents1 and exhibit 1 year patency rates comparable to bypass surgery.2 Still, with reported 3 year primary and secondary patency rates for heparin-bonded endografts of 59% and 82%, respectively, complications and reinterventions are not uncommon.3,4 Endograft thrombosis in particular may have a major impact as it can cause a compartment syndrome after revascularization or limb loss. The development of an edge stenosis that limits and/or disturbs blood flow through the endograft is commonly considered as an important risk factor for endograft thrombosis. This is supported by observations that an edge stenosis was present in 75% of thrombosed endografts,5 mostly at the proximal edge of the endograft. Although the introduction of a contoured proximal graft edge and the strategy of minimizing oversizing might reduce the incidence of edge stenosis, edge stenosis is still a common complication in treated patients and may predispose to thrombosis.6

A contributor to the risk on the development of a proximal edge stenosis and endograft thrombosis may be the proximity of the endograft to the femoral bifurcation. The
flow division at the bifurcation may generate focal areas of slow and recirculating flow that, if persistent over the cardiac cycle, are likely to promote anastomotic intimal hyperplasia or thrombus formation.7,8 These areas of stasis of blood are undetectable by current clinical imaging modalities including duplex ultrasound and contrast-enhanced computed tomography (CTA). Imaging-based computational fluid dynamics (CFD) can compute the complete 3D flow field over time in patient geometries and therefore has potential value for diagnosing these areas of slow and recirculating flow in patients. Computational fluid dynamics has a proven track record for diagnosing the hemodynamic significance of coronary artery disease.9 For arterial thrombosis, CFD has been applied for understanding thrombosis for bare metal stents in coronary arteries10 and carotid arteries,11 as well as for exploring hemodynamic causes of intraluminal thrombus in cerebral aneurysms12 and aortic aneurysms.13 In addition, a few hypothesis-generating studies for endograft thrombosis in stented carotid,14 aortic,15,16 and femoropopliteal17 arteries have been described. However, most of the studies on stented arteries have not correlated the hemodynamic simulations with longitudinal patient follow-up. Moreover, none of these studies have assessed the value of CFD for predicting endograft thrombosis, as none included a set of control cases in which no thrombosis occurred. Here we demonstrate the clinical feasibility of patient-specific CFD in 4 patients treated with an endograft in the superficial femoral artery (SFA), of which half experienced endograft thrombosis on follow-up. By comparing simulation results for patients with and without endograft thrombosis, the value of CFD for predicting endograft complications is investigated.

Materials and Methods

Clinical Cases

Four patients were selected with a successful recanalization of an occluded SFA by the placement of an expanded polytetrafluoroethylene endograft (Heparin-bonded Viabahn; W.L. Gore & Associates, Flagstaff, AZ, USA). In 3 of these patients, an additional thromboendarterectomy of the common femoral artery (CFA) was performed. In all cases, the proximal end of the endograft was near the femoral bifurcation (<3 cm). The indication for intervention was Rutherford 3 (n=1), 4 (n=1), and 6 (n=2), respectively. Dual anti-platelet (acetylsalicylic acid 80 mg 1 dd and clopidogrel 75 mg 1 dd) was prescribed for 3 months followed by a single antiplatelet regimen. Patient characteristics and procedural details are provided in Table 1 and procedural images are shown in Figure 1. This study was approved by the competent institutional review board and written informed consent for data publication was provided by all participants.

Computational Fluid Dynamics

Physical flow equations of 3-dimensional blood flow were solved with patient-specific CFD simulations. The CFD model employed the patient’s anatomy segmented from CTA and duplex ultrasound measurements for the boundary conditions, as illustrated in Supplemental Figure 1.

A CTA with 0.9 mm slice thickness (IQon spectral CT with iDose reconstruction, Philips Healthcare, Amsterdam, the Netherlands) was used for reconstruction of the geometry. For segmentation and smoothing of the arterial lumen, the vmtkLab software (v1.6.1, Orobix, Bergamo, Italy) employing a level-set technique based on implicit active surfaces18 was used. This segmentation technique utilizes a deformable 3D-geometry that is simultaneously deformed to conform to user-weighted constraints on attraction to the vessel lumen boundary and surface model curvature. Only high-level choices such as vessel selection, a single lumen boundary weight and a single curvature weight per vessel can be made by the user, which provides a high inter- and intraoperator repeatability of the segmentation.19,20 The 3 major femoral arteries were segmented, without inclusion of the lateral circumflex artery stemming from the deep femoral artery (DFA).

To derive the inlet and outlet boundary conditions, the centerline velocities measured with duplex ultrasound at the CFA, proximal DFA and mid SFA were used to compute time-varying flow rates by assuming a fully developed Womersley profile, which provides an explicit relation between centerline velocity and flow rate.21 For the DFA, the peak velocity was measured relatively close to the femoral bifurcation, which could have led to overestimation of total volume flow here by the fully developed flow assumption. The measured CFA flow profile was imposed at the inlet as a Womersley velocity profile and a 3-element Windkessel was applied at the SFA and DFA outlets, tuned to match the measured flow profiles. The values obtained after tuning the Windkessel outlets are shown in Supplementary Table 1.

The timing of the CTA and hematocrit levels for the CFD simulation are depicted in Table 1, with further details on modeling choices and the SimVascular CFD solver22 in the expanded methods section. The CFD solver has been validated against phase-contrast magnetic resonance imaging (PC-MRI) in realistic patient geometries.23 From the CFD solution, the time-averaged wall shear stress (TAWSS) over 1 cardiac cycle was calculated. Areas of low TAWSS correspond to sites of recirculating flow, and a TAWSS < 0.4 Pa has been associated with proatherogenic endothelial activity.24 In the context of graft thrombosis, low TAWSS translates to a decreased washout of particles, leading to prolonged residence times of blood particles. In vitro studies have demonstrated the preferential accumulation of fibrin networks at sites of low TAWSS.25 The full modeling
process, including segmentation and postprocessing, could be completed in approximately 7 hours, consisting of 3 hour human labor and 4 hour computational time (~45 minutes per cardiac cycle) on an entry-level 64 core computational cluster (4 × 16 core Opteron 6376, Advanced Micro Devices, Santa Clara, CA, USA). Segmentation was the most time-intensive process of the human labor, in part because a computationally expensive segmentation method was used to meet the stringent requirements CFD puts on continuity and smoothness of the geometry. This method can likely be significantly sped up with numerical optimizations.

**Results**

**Clinical Follow-Up**

All patients had a good short-term follow-up, with no abnormalities observed on 6 week duplex ultrasound. Afterward, case 1 developed a popliteal stenosis ~8 cm distal from the distal edge of the endograft, with a peak systolic velocity ratio > 6 that was treated at 7 months using plain balloon angioplasty (PBA) and a drug-coated balloon (DCB) (IN. PACT Admiral, Medtronic, Minneapolis, MN). Thereafter the follow-up was uneventful up to the latest follow-up at 26 months. Case 2 was characterized by a progressive stenosis in the CFA, which was treated by PBA at 4 month follow-up (Figure 2A). A CTA was made at 7 months follow-up for planning of a thromboendarterectomy of the contralateral CFA. The ipsilateral CFA restenosis resurfaced at 11 months follow-up, which was treated for a second time with PBA. At 20 month follow-up, an ipsilateral in-stent stenosis >50% was observed on duplex ultrasound (Figure 2A) and treated with PBA. No further complications occurred up to the patient’s death at 41 months.

Patient 3 presented twice with an acute occlusion of the endograft at 8 and 28 months, respectively. Both were successfully treated with catheter-directed thrombolysis, although the second treatment was complicated by a compartment syndrome treated with fasciotomy. During the first thrombolysis, a stenosis near the proximal edge of the endograft was observed (Figure 2B) and treated with PBA. In
addition, antithrombotic medication was temporarily changed to coumadin, which was reverted to single anti-platelet therapy after 6 months. The inflow stenosis resurfaced at the second thrombolysis (Figure 2B) and was treated with a DCB. Antithrombotic medication was switched indefinitely to coumadin thereafter. To identify other potential causes of the recurring occlusion, the distal vasculature was evaluated with CTA and duplex ultrasound, both showing patency of the SFA without restenosis and a 3 vessel distal run-off. Nonetheless, routine duplex ultrasound follow-up demonstrated reocclusion of the endograft half a year later, which was left untreated in the absence of symptoms.

Patient 4 presented with a cold leg and sudden decrease in walking distance caused by an occlusion at 4, 7, and 10 months, all successfully mitigated by catheter-directed thrombolysis. After the first thrombolysis, the patient was switched from a single anti-platelet regimen to coumadin. During the second thrombolysis, a proximal region in the endograft devoid of contrast was found (Figure 2C), which did not fully resolve after PBA. Therefore, a 5 cm long second endograft was inserted in the first one up to the level of the femoral bifurcation (Figure 2C). This did not prevent a third occlusion, though. After the third thrombolysis, the endograft remained patent for the current 5 month follow-up period.
Figure 2. DSA-images for a selection of secondary treatments. All marked lesions were treated with PTA, with the addition of a drug-coated balloon for the recurring inflow stenosis in the SFA (B bottom). An area devoid of contrast was found in the proximal Viabahn for case 4 (C top), attributed to fibrin deposition, treated with PTA and a proximal extension with a second Viabahn stent graft (C bottom). CFA, common femoral artery; DFA, deep femoral artery; PTA, posterior tibial artery; SFA, superficial femoral artery.
Personalized Flow Simulations

Instantaneous velocity streamlines for key phases of the cardiac cycle and TAWSS contours are shown in Figures 3–6 for all patients. Streamlines during the full cardiac cycle are animated in Videos 1–4. In all cases, flow separation was present most distinctively during systolic deceleration (timepoint tB). Case 1 was characterized by a...
widened CFA by patch angioplasty, which led to flow separation in the CFA. In addition, a slight narrowing at the origin of the SFA (and stent) was present, associated with modest flow separation in the SFA (Figure 3B). The flow separation in the CFA was associated with low TAWSS (<0.4 Pa, Figure 3E), which was not the case for the SFA where only a tiny streak of TAWSS < 0.4 Pa is present. Case 2 was characterized by a 50%-area stenosis in the
CFA, creating high flow velocities and areas of helical or swirling flow, especially in the SFA (Figure 4A and B). The swirling flows with relatively high velocities were not associated with low TAWSS.
For case 3, flow separated in the SFA at multiple locations at the end of systole, in particular in a region encompassing the site of the recurrent inflow stenosis and at the endograft’s proximal edge. These zones with low flow velocity and recirculation were sustained during diastole (Figure 5C). Case 3 was the only case that exhibited monophasic flow on duplex ultrasound (Figure 5D), so no wash-out of low flow regions by backflow was present. Less...
consistent regions of flow separation were present more
distal in the SFA endograft. The areas of flow separation in
the SFA were associated with very low TAWSS, with values
below 0.05 Pa (Figure 5E). These areas of minimal wall
shear stress coincided with the location of the former inflow
stenosis and the proximal edge of the endograft.

Similarly, for case 4, flow separation at multiple regions
in the SFA was present, especially near the bifurcation
(Figure 6B). Recirculating flow was also present in the
cFA, which widens close to the bifurcation. Low values of
TAWSS were seen at these sites, covering the full proximal
SFA with values below 0.15 Pa (Figure 6E). The area in the
proximal SFA devoid of contrast during the second throm-
bolysis, exhibited a zone of minimal TAWSS, with values
below 0.01 Pa.

Discussion

This hypothesis-generating study suggests that personal-
ized CFD simulations can predict flow-induced complica-
tions in endografts in the SFA, where standard diagnostic
imaging techniques failed to do so. The CFD simulations
demonstrated pronounced areas of low TAWSS in the 2
cases that presented with a repetitive recurrent thrombosis
of the endograft (patients 3 and 4). Areas of low TAWSS
originated from zones of flow separation during systolic
deceleration in cases 1, 3 and 4, which potentially associate
with the lower velocities measured in the SFA, both in
absolute terms and relative to DFA velocity. The flow sepa-
ration generates adverse flow patterns, which can be stabi-
ized by the backflow phase as in case 1, although this
stabilization did not occur in case 4 despite similar triphasic
flow. As the geometry and duplex-derived flow rates of
case 1 and 4 were not very dissimilar, these cases demon-
strate that the relevant flow features are difficult to derive
from standard duplex and imaging data alone. Therefore,
advanced techniques of flow characterization may offer
clinical value for optimizing endograft treatment of occlusive
disease of the SFA.

The underlying pathologic mechanism of endograft
thrombosis is a complex multifactorial process, in which
personalized CFD simulations could help unveil the contri-
bution of flow separation, stasis of blood, and shearing
forces. For this case of arterial coagulation, Virchow’s triad
of surface susceptibility, hypercoagulability, and flow sta-
sis likely all are important actors, possibly supplemented
by shear-rate induced platelet activation. It is well docu-
dmented that an endothelial layer does not form in surgically
implanted ePTFE grafts in senescent humans, except for, at
most, a ~1 cm region at either anastomosis. Likewise for
ePTFE endografts, a stable endothelial layer does not seem
to exceed 2 to 3 cm from the edges, with the remainder of
the inner graft lining being covered by a layer of fibrin,
mostly acellular, but possibly interspersed with platelets
and granulocytes. It is unclear if these fibrin layers event-
ually develop on the heparin-bonded Viabahn, for which
no histopathologic studies were found. Although the hepa-
rin-bonded luminal surface was shown to reduce thrombin
activity in human blood, the graft surface remains more
thrombogenic than endothelial-lined vessel walls. Over
time, fibrin depositions may accumulate into macroscopic
thrombus, especially at areas where residence time of
blood particles is prolonged and where shear forces are
small, that is, at sites of low TAWSS. This process can be
accelerated by adverse flow patterns induced by an edge
stenosis, which originates from anastomotic intimal hyper-
plasia at the graft edges.

In the cases studied here, large areas with TAWSS below
0.15 Pa were present in the stent grafts that thrombosed
cases 3 and 4), but a small area with minima of 0.05 Pa was
also present in one of the patent stents grafts (case 1). It is
difficult to decide a precise cut-off level at which
deposition occurs. A previous study has linked WSS below
0.17 Pa and below 0.41 Pa for a Newtonian fluid and for a
shear-thinning viscosity model, respectively, to thrombus
deposition in in-vitro flow loops. The cut-off for Newtonian
CFD models at 0.17 Pa is of similar order as the adverse
tAWSS levels observed in our cases. However, the shear-
thinning cut-off at 0.41 Pa demonstrated a better fit to the
experimental results in the mentioned study, but cannot be
applied to our CFD results due to the assumed Newtonian
behavior. Future computational studies of in-stent thrombo-
sis may therefore benefit from using more complex viscosity
models.

The hypothesized fibrin deposition at areas of low
TAWSS may be especially relevant for endografts placed in
the proximal SFA, as the underlying fluid mechanics pre-
dicts sites of flow separation in the region downstream of
major bifurcations. The presence of such a pathophysi-
ologic mechanism cannot be imaged by anatomic scanning
or current duplex ultrasound techniques, but requires
assessment of the 3D time-resolved vector flow field in
endograft. At present, this can be accomplished by a costly
time-consuming 3D PC-MRI, by upcoming 3D ultra-
fast ultrasound techniques or by the present patient-spe-
cific CFD method, based on anatomic input by either CTA,
MRA, or rotational angiography, and based on flow input for
the 3 femoral arteries by duplex ultrasound. An advantage
of CFD is that the effect of a treatment option on the persis-
tence of adverse flow can be simulated, which could pro-
vide treatment decision support. Furthermore, material cost
of CFD simulations is very low in comparison with other
flow imaging techniques. Obviously, the suggested role of
CFD in treatment decision support needs further clinical
evidence of the hypothesized link between low TAWSS and
endograft thrombosis.

To exemplify CFD treatment decision support for case 3,
we investigated whether PBA of the luminal narrowing
immediately upstream from the endograft could mitigate the low TAWSS region at the proximal stent edge. After virtual angioplasty of this vessel region by cylindrical inflation, CFD simulations with similar boundary conditions did not show a qualitative change of the localization of low TAWSS regions. However, at the proximal border of the endograft, the minimal value of TAWSS strongly increased from 0.015 to 0.1 Pa. When further substantiated by clinical evidence of the hypothesized association between TAWSS and endograft thrombosis, this could serve as an indication to perform PBA of the luminal narrowing to extend patency of the endograft. A more immediate implementation of CFD would be to personalize patient follow-up intervals and/or antithrombotic medication based on a risk stratification by TAWSS levels in and around the treated SFA.

Several limitations of the simulations and flow analysis warrant consideration in future studies. First, the used CTA images were performed at varying times during follow-up and do not accurately reflect the geometry after treatment. However, as all CTAs were made at 6M or later, the vascular geometry is not expected to change much as most vascular remodeling in response to treatment occurs within the first months. Second, the CFD simulations involve several simplifications and the accuracy of the simulations is dependent on the used CTA and duplex ultrasound input data, which were recorded in supine position and may be subject to change in other postural positions. The effect of the most important CFD modeling simplifications on WSS in bifurcating flows are a fully-developed velocity profile at the inlet (~10% change in TAWSS), a Newtonian behavior of blood (<10% change in TAWSS), and a rigid wall assumption (~5% change in TAWSS). Although the absolute values of TAWSS in our simulations can be impacted by these simplifications, the referenced studies have shown that the localization of low TAWSS areas are not altered by these simplifications. Therefore, the low TAWSS values in our patient cases with occlusion relative to normal TAWSS values in control cases is a result that is likely not affected by these assumptions. As shown in a subset of these sensitivity studies, the major contributor to possible inaccuracies in the CFD results is uncertainty in CTA and duplex ultrasound input data. Main challenges for this study were segmentation of the endograft and the difficulty of obtaining strong duplex ultrasound signals in the DFA. The endograft segmentation resulted in a relatively smooth endograft inner surface, although it is known that some protrusions by the stent wires are present, which are not visible on CTA. These create some local fluctuations in TAWSS in the order of 0.05 Pa, which is small compared with the intra- and interpatient differences in our study. The impact of the sub-optimal DFA duplex ultrasound signal is harder to assess and should be quantified in prospective clinical studies where duplex ultrasound data acquisition can be optimized for this specific purpose.

Finally, TAWSS is a somewhat surrogate measure of particle residence time and shearing forces, and more elaborate measures like wall shear stress exposure time and wall shear stress divergence may be better predictors of thrombus development. For reasonably laminar flow as present in the current cases, the differences are not as significant as for more complex transitional flows in abdominal aortic aneurysms, however. A prospective cohort study in a larger patient population with standardized image acquisition and follow-up would be ideally suited to address these limitations and to substantiate the hypothesized relation between wall shear stress and endograft thrombosis.

Conclusion

Personalized CFD simulations demonstrated areas of low wall shear stress (TAWSS < 0.15 Pa) in the SFA endograft for 2 out of 4 patient cases. The presence of low wall shear stress was associated with recurrent events of endograft thrombosis, despite an otherwise normal anatomic and ultrasound assessment and a good distal run-off.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.R. has received research funding and speaker fees from W.L. Gore & Associates.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Lennart van de Velde https://orcid.org/0000-0001-8804-8671
Erik Groot Jebbink https://orcid.org/0000-0001-7041-8603
Michel Versluis https://orcid.org/0000-0002-2296-1860
Michel M. P. J. Reijnen https://orcid.org/0000-0002-5021-1768

Supplemental Material

Supplemental material for this article is available online.

References


